Search

Siyasal kimlik kültürel kimliğin politikleşmesi veya bireyin içinde bulunduğu koşulları politikleştirerek edindiği bir kimliktir. Diğer kimlikler gibi siyasal kimlik de bir süreç içinde oluşmaktadır. Bu süreç siyasal toplumsallaşma olarak kavramsallaştırılmaktadır. Dolayısıyla bireyler siyasal toplumsallaşma sürecinde bu kimlikleri benimsemektedirler. Siyasal toplumsallaşma sürecinde aile, çevre, okul ve kitle iletişim araçları gibi etkenler bireyin siyasal bir kimlik edinmesinde önemli yer tutmaktadır. Siyasal kimliğin ediniminde aile çoğu zaman belirleyici bir rol oynamaktadır. Özellikle ailenin hala önemli bir kurum olduğu Türk toplumunda bu rol daha baskın çıkabilmektedir. Aile kurumu bireylerin ilk sosyalleştiği kurum olması dolayısıyla kalıcı bir etki oluşturmaktadır. Dolayısıyla siyasal etkileşimin gerçekleştiği, siyasal davranışın şekillendiği ve siyasal tutumların edinildiği bir kurum olarak aile siyasal kimlikle yakın bir ilişki içerisindedir. Bu çalışma Türkiye’deki siyasal kimliklerden biri olan solcu kimliğinin benimsenmesinde ailenin nasıl bir rol oynadığını alandan elde edilen verilerle tespit etmeyi amaçlamaktadır. Alan araştırmasına dayalı olarak yürütülen bu çalışmada nitel araştırma yöntemi esas alınacaktır. Verilerin toplanması için de derinlemesine görüşme tekniği kullanılacaktır. Toplanan veriler betimsel analiz tekniğiyle analiz edilecek ve yorumlanacaktır. Çalışmada elde edilen sonuçlardan biri de Türk toplumunda ailenin siyasal kimliğin şekillenmesinde hala belirleyici önemini koruduğu görülmektedir. Fakat ailenin dışında eğitim ve sosyal çevrenin de bireylerin siyasal kimliğinin oluşması üzerinde önemli bir etkisi vardır.

Background: Kaposi sarcoma (KS) is a multicentric vascular and lymphatic neoplasm caused by human herpesvirus 8 (HHV-8). It generally concerns the elderly and immunosuppressed population. Four major clinical types of KS have been described. The most common subtype is Classical KS (CKS)., Objectives: Our retrospective study aimed to better define prognostic subgroups among patients with CKS, which is the most common in our country., Method: Between 2014 and 2020, 43 patients with CKS were treated with local excision, radiotherapy and chemotherapy. Reviewed information included demographics, clinical features, laboratory findings, treatment responses and overall survival., Results: During the follow-up, eight patients (18.6%) died of CKS. The complete response rate was 46.5%, partial response and stable disease 51.2%, and progressive disease 2.3% of all patients. Gender, haemoglobin level at diagnosis, and disseminated involvement were prognostic factors affecting survival in all patients., Conclusion: We confirmed that male gender, low haemoglobin levels, and disseminated involvement are associated with poor prognosis in CKS patients. It is the only Turkish study in which prognostic analysis was performed for this rare cancer., (© 2024 Australasian College of Dermatologists.)

Majority of patients with breast cancer were diagnosed with locally advanced stages of the disease (54%). This study aimed to explain the pathological response received to neoadjuvant chemotherapy (NACT) according to the molecular classification of breast cancer in patients with locally advanced tumors. One hundred and one patients with locally advanced breast cancer treated with neoadjuvant chemotherapy were analyzed. Patients were classified into five molecular subtypes based on the profile of the estrogen receptor, progesterone receptor, HER2, and Ki-67. We determined associations between complete pathological response (no invasive tumor after neoadjuvant chemotherapy) and molecular subgroups. Most patients had luminal A tumors (n: 28, 27.7%). The overall rate of complete pathological response (pCR) was 34.7% (n:35). Tumors that presented with the highest rate of pCR were pure HER2-positive, at 60% (n:6; OR, 3.2; 95% CI, 0.8-12.2). According to logistic regression analysis, the factors affecting pCR were HER2 positivity and clinically positive axilla before NACT. Luminal A tumors had a significantly lower pCR rate. (7.1%,p: 0.001). Despite the low pCR rate, Luminal A tumor had the best survival rate in the subgroups ( p  < 0.001). However, there was no difference between EFS and OS according to pCR in any molecular subgroups. Pathological complete response is directly related to the subtypes of breast cancer. A high complete pathological response rate is observed in the pure HER2-positive group. However, EFS and OS were not statistically significant in patients with and without pCR.

Introduction: Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor receptor, is the standard treatment of recurrent glioblastoma multiforme. In addition to common systemic side effects of bevacizumab, there are rare cases of cranial nerve palsy., Case Report: We report a case of transient oculomotor nerve palsy after systemic administration of bevacizumab. Twenty-four hours after the systemic infusion of bevacizumab, transient oculomotor nerve palsy developed in a 49-year-old male patient. In the cranial MRI, there was no malignancy-related progression., Management and Outcome: Bevacizumab treatment was discontinued. Methylprednisolone was started considering that bevacizumab increased the inflammatory response. Oculomotor nerve palsy resolved in 14 days., Discussion: There are many side effects of bevacizumab whose mechanisms of action have not been fully explained. Cranial nerve involvement is rarely reported. Our case is the first reported case of bevacizumab-induced oculomotor nerve palsy.

Undoubtedly, cancer patients have suffered the most from the COVID-19 pandemic process. However, cancer is a heterogeneous disease, and each patient has responded differently to COVID-19. We aimed to describe the clinical characteristics and outcomes of patients with cancer and COVID-19. We retrospectively reviewed 45 cancer patients hospitalized in the Cerrahpaşa Medical Faculty COVID-19 department from March 23 to October 23, 2020. We analyzed the demographic characteristics, symptoms, laboratory findings, treatment, prognosis, and cancer subtypes of patients and mortality who were hospitalized for COVID-19. Between March 23 and October 23, 2020, 45 hospitalized cancer patients who had laboratory-confirmed COVID-19 infection were included, with a median age of 60 years (range: 23-92). Patients were divided into two groups a survivor and a non-survivor. Symptoms, demographic information, comorbidities, treatments for COVID-19, and laboratory findings of the two groups were evaluated separately. Two parameters were found, which showed a significant difference between non-survivors and survivors displaying a disadvantage for COPD and low platelet count (p = 0.044-0.038). The mortality rate of all patients was 66%. The presence of comorbidities such as COPD and low platelet count in cancer patients with COVID-19 infection may draw the attention of physicians., (© 2021 Wiley Periodicals LLC.)